Fig. 3.

Immunostimulatory sequence (ISS) inhibits myeloid dendritic cells (mDC) migration into the lung of mice in vivo. (A) Schematic illustration of the experimental protocol. Mice were sensitized with ovalbumin (OVA)/alum and ISS was administered intraperitoneally on day 19. Intranasal OVA challenge was performed on days 20 and 25, and this experiment was performed in duplicate. (B) CD11c+CD11b+ cell counts increased from 1.84% to 15.80% after OVA challenge and decreased to 9.02% in the ISS administration group. In the case of CD11c+B220+ cells, counts increased from 0.60% to 1.08% after OVA challenge, and then decreased to 0.69% after ISS administration. (C) ISS administration significantly lowered eosinophil counts and Th2 cytokine (IL-4 and IL-5) levels in BAL fluid (all, P<0.01).